STAAR Surgical (NASDAQ:STAA) Exceeds Q1 Expectations
Medical lens company STAAR Surgical (NASDAQ:STAA) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 44.9% year on year to $42.59 million. Its GAAP loss of $1.10 per share was 65.2% below analysts' consensus estimates.
Is now the time to buy STAAR Surgical? Find out in our full research report.
STAAR Surgical (STAA) Q1 CY2025 Highlights:
Revenue: $42.59 million vs analyst estimates of $40.35 million (44.9% year-on-year decline, 5.5% beat)
EPS (GAAP): -$1.10 vs analyst expectations of -$0.67 (65.2% miss)
Adjusted EBITDA: -$26.39 million vs analyst estimates of -$26.51 million (-62% margin, in line)
Operating Margin: -135%, down from -2.9% in the same quarter last year
Free Cash Flow was -$7.20 million, down from $16.48 million in the same quarter last year
Constant Currency Revenue fell 44.3% year on year (6.5% in the same quarter last year)
Market Capitalization: $922.9 million
'STAAR's first quarter sales were in line with expectations, but we can and will do better,' said STAAR Surgical CEO, Stephen C. Farrell.
Company Overview
With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens.
Sales Growth
A company's long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, STAAR Surgical's sales grew at a solid 12.8% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.
STAAR Surgical Quarterly Revenue
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. STAAR Surgical's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 2.7% over the last two years.
STAAR Surgical Year-On-Year Revenue Growth
We can dig further into the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 1.9% year-on-year declines. Because this number aligns with its normal revenue growth, we can see that STAAR Surgical has properly hedged its foreign currency exposure.
STAAR Surgical Constant Currency Revenue Growth
This quarter, STAAR Surgical's revenue fell by 44.9% year on year to $42.59 million but beat Wall Street's estimates by 5.5%.
Looking ahead, sell-side analysts expect revenue to grow 3.4% over the next 12 months. While this projection suggests its newer products and services will spur better top-line performance, it is still below the sector average.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO
-- Insurance technology company Slide is pursuing a valuation of up to $2.12 billion in its upcoming initial public offering (IPO) on the Nasdaq exchange. The company disclosed the target in a filing on Monday. In collaboration with some of its existing stakeholders, Slide is aiming to raise up to $340 million from the IPO. This move is in line with a recent trend of successful stock market debuts by insurance firms. Barclays and Morgan Stanley have been named as the lead underwriters for the listing. The shares of the company are anticipated to begin trading on the Nasdaq exchange under the ticker symbol "SLDE". Related articles Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO Morgan Stanley downgrades Lululemon on weak US growth outlook Tesla shares slip after double downgrade amid Trump feud fallout Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio
CBS News
an hour ago
- CBS News
For Philadelphia's Strawberry Mansion neighborhood, potential SEPTA cuts would be devastating
In Philadelphia's Strawberry Mansion neighborhood, half the residents don't own cars. For them, public transportation is essential, not a choice. Neighbors like Marcella Bevins rely on SEPTA to get to doctor's appointments several times a month. "I got to my oncologist, that's the 49 bus to go to Civic Center ... I catch the 49 to go to 30th Street Station to catch the El," said Bevins, a Strawberry Mansion resident. But SEPTA's $213 million budget deficit is pushing the agency to shrink the system. It plans to cut 50 bus routes and five Regional Rail lines and reduce service across the board. Strawberry Mansion will be hit especially hard. Nine routes through the neighborhood could be discontinued or reduced by up to 20%. "I don't know what SEPTA is doing; they raised the fare, and then they want to cut routes. That doesn't make sense," Bevins said. "They feel like it's an attack on them and their life. It's a food desert. Not a lot of places to get groceries, and they've got relatives across the city they want to visit," Jalon Alexander, an attorney and community advocate, said. Alexander hosted a meeting on Monday at Garden of Prayer Church, bringing neighbors, SEPTA officials and lawmakers together. "Candidly, SEPTA's the victim here. SEPTA needs funding to thrive," Alexander said. Right now, SEPTA funding depends on lawmakers in Harrisburg, who have until June 30 to include SEPTA in the state budget, just ahead of the transit agency's own deadline. "The money that needs to be spent is nothing compared to the money that will be lost if we do not fund SEPTA," state Sen. Sharif Street said. When service cuts go into effect beginning Aug. 24, SEPTA said affected riders will still be able to use alternate routes to get to their destinations. However, that could include more transfers, and most people's commutes may be longer and more complicated. "If I've got to catch another bus when I've been catching the same bus for 25 years to get to and from work, that's going to cost me more. That affects my budget," Tyrone Williams, of Strawberry Mansion Community Development, said. It also affects their jobs, health, families and daily survival. The Strawberry Mansion community said decisions about service cuts shouldn't be made without their voices at the table. "I think SEPTA attending the meeting today reflects their commitment to work with the community as a team because they're an integral part of our lives," Alexander said.
